Literature DB >> 29963683

Mortality in Patients with Bullous Pemphigoid: A Retrospective Cohort Study, Systematic Review and Meta-analysis.

Khalaf Kridin1, Wesal Shihade, Reuven Bergman.   

Abstract

There is little consensus regarding mortality data in bullous pemphigoid (BP). The aim of this study was to evaluate mortality among a relatively large cohort of Israeli patients with BP and to perform a meta-analysis synthesizing existing data on 1-year mortality rates of patients with BP. This retrospective cohort study of 287 patients diagnosed with BP between 2000 and 2015 compared the mortality of patients with BP with age- and sex-matched control subjects in the general population. The results showed 1-, 5- and 10-year mortality rates of 26.9%, 56.9% and 69.5%, respectively, and a 3.4-fold higher risk of death. A systematic review and meta-analysis were then performed using a random effects model. Including the current study, 25 studies comprising 4,594 patients met the eligibility criteria. The pooled estimate of 1-year mortality rate was 23.5% (95% confidence interval 20.2-26.8; I2=81%; p < 0.001). The pooled 1-year mortality rate of European cohorts was prominently higher relative to the pooled rates of cohorts from the USA and Asia.

Entities:  

Keywords:  bullouspemphigoid; meta-analysis; mortality; prognosis; survival; systematicreview

Mesh:

Year:  2019        PMID: 29963683     DOI: 10.2340/00015555-2930

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  11 in total

1.  Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.

Authors:  Arata Hibi; Yuto Kasahara; Yoshitaka Ishihara; Koichi Hata; Norihisa Hosokawa; Takahiko Nakagawa
Journal:  CEN Case Rep       Date:  2020-01-28

Review 2.  The Immunogenetics of Autoimmune Blistering Diseases.

Authors:  Diana Kneiber; Eric H Kowalski; Kyle T Amber
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.

Authors:  Yun-Ju Tsai; Yung-Tsu Cho; Chia-Yu Chu
Journal:  Am J Clin Dermatol       Date:  2022-05-17       Impact factor: 6.233

4.  Successful Treatment of Bullous Pemphigoid Lesions by Berberine Stamp Therapy: A Case Report and Literature Review.

Authors:  Linyan Cheng; Yi Wang; Hanzhi Lu; Wanjun Guo; Ge Yan; Jianyong Zhu; Dongjie Guo; Fulun Li
Journal:  Front Med (Lausanne)       Date:  2022-07-01

Review 5.  Drug Development in Pemphigoid Diseases.

Authors:  Katja Bieber; Ralf J Ludwig
Journal:  Acta Derm Venereol       Date:  2020-02-12       Impact factor: 3.875

Review 6.  Bullous pemphigoid.

Authors:  Denise Miyamoto; Claudia Giuli Santi; Valéria Aoki; Celina Wakisaka Maruta
Journal:  An Bras Dermatol       Date:  2019-05-09       Impact factor: 1.896

Review 7.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Kaisa Tasanen; Outi Varpuluoma; Wataru Nishie
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 8.786

Review 8.  Coagulation and Skin Autoimmunity.

Authors:  Massimo Cugno; Alessandro Borghi; Simone Garcovich; Angelo Valerio Marzano
Journal:  Front Immunol       Date:  2019-06-20       Impact factor: 7.561

Review 9.  Bullous Autoimmune Dermatoses–Clinical Features, Diagnostic Evaluation, and Treatment Options.

Authors:  Nina van Beek; Detlef Zillikens; Enno Schmidt
Journal:  Dtsch Arztebl Int       Date:  2021-06-18       Impact factor: 8.251

10.  Bullous Pemphigoid After Total Knee Arthroplasty.

Authors:  Suleiman Sudah; Christopher Michel; Christopher Dijanic; Daniel Kerrigan; Mark Gesell
Journal:  Arthroplast Today       Date:  2021-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.